Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561394 | 0.93 | EPHX1 (0.48) | EPHX1TSHREPHX2PRMT1CA12 | |
| SCHEMBL4419366 | 0.91 | EPHX1 (0.47) | EPHX1TSHREPHX2PRMT1CA12 | |
| SCHEMBL4362272 | 0.89 | EPHX1 (0.55) | EPHX1EPHX2PRMT1CA12CA1 | |
| SCHEMBL254189 | 0.89 | EPHX1 (0.46) | EPHX1TSHREPHX2PRMT1MEN1 | |
| SCHEMBL28435450 | 0.87 | EPHX1 (0.55) | EPHX1EPHX2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21360055 | 0.87 | EPHX1 (0.44) | EPHX1TSHREPHX2PRMT1CA12 | |
| SCHEMBL4355762 | 0.87 | EPHX1 (0.57) | EPHX1EPHX2 | |
| SCHEMBL19838195 | 0.87 | EPHX1 (0.52) | EPHX1EPHX2PRMT1CA12CA1 | |
| SCHEMBL9985974 | 0.86 | EPHX1 (0.33) | EPHX1TSHRCA12CA1CA2 | |
| SCHEMBL10557593 | 0.85 | EPHX1 (0.57) | EPHX1EPHX2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138501-B1 | Functional silane compound, coating solution, and method for manufacturing plastic lens | HOYA CORP (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2138501-B1 | Functional silane compound, coating solution, and method for manufacturing plastic lens | HOYA CORP (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2138501-A2 | Functional silane compound, coating solution, and method for manufacturing plastic lens | Hoya Corporation (JP) | 2009-12-30 | — | — | EP | disclosed |
| US-20090317541-A1 | FUNCTIONAL SILANE COMPOUND, COATING SOLUTION, AND METHOD FOR MANUFACTURING PLASTIC LENS | HOYA CORPORATION (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-0216868-A1 | AN AUTO-ADHERING ONE-COMPONENT RTV SILICONE SEALANT COMPOSITION UTILIZING AN ADHESION PROMOTER | LOCTITE CORPORATION (US) | 1987-04-08 | — | — | EP | disclosed |
| WO-1986005798-A1 | AN AUTO-ADHERING ONE-COMPONENT RTV SILICONE SEALANT COMPOSITION UTILIZING AN ADHESION PROMOTER | LOCTITE CORPORATION (US) | 1986-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317541-A1 | FUNCTIONAL SILANE COMPOUND, COATING SOLUTION, AND METHOD FOR MANUFACTURING PLASTIC LENS | SUMO1, CAD, UFM1 | EPHX1 4148/4885TSHR 4052/4885EPHX2 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.